Fig. 4: Sorafenib plasma levels in all study samples, as compared with published pharmacokinetic data. | British Journal of Cancer

Fig. 4: Sorafenib plasma levels in all study samples, as compared with published pharmacokinetic data.

From: Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial

Fig. 4: Sorafenib plasma levels in all study samples, as compared with published pharmacokinetic data.

Plasma concentrations from patients treated with SIRT plus sorafenib are represented by circles (where the time after dose is known) or diamonds (where the time after dose in not known, arbitrarily shown mid-dosing interval). For graphical purposes, two samples with high levels of sorafenib ( > 19,000 ng/mL) are not shown. Pharmacokinetic curves were retrieved and adapted from Jain et al. for five patients receiving sorafenib 400 mg BID (blue) or 200 mg BID (red), with solid lines indicating the median and broken lines indicating the 25th and 75th percentiles. Data points shown at 12 h correspond to any trough levels measured at 12 or 24 h. BID twice daily, SIRT selective internal radiation therapy.

Back to article page